Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.38 |
| ▸ | KISS1R | Q969F8 | 2/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | CARM1 | Q86X55 | 2/20 | 0.32 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | USP2 | O75604 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3753850 | 0.87 | TSHR (0.42) | TSHRSMN1; SMN2KDM4EALDH1A1MEN1 | |
| Diethanolamine SCHEMBL20358122 | 0.84 | KDM4E (0.41) | TSHRSMN1; SMN2KDM4EKISS1RALDH1A1 | |
| SCHEMBL3030823 | 0.83 | KISS1R (0.35) | SMN1; SMN2KDM4EKISS1RALDH1A1CARM1 | |
| SCHEMBL3030406 | 0.82 | KDM4E (0.40) | SMN1; SMN2KDM4EKISS1RALDH1A1CARM1 | |
| SCHEMBL13492697 | 0.81 | ANPEP (0.41) | TSHRSMN1; SMN2KDM4EKISS1RCARM1 | |
| SCHEMBL15641242 | 0.79 | SMN1; SMN2 (0.36) | TSHRSMN1; SMN2KDM4EALDH1A1MEN1 | |
| SCHEMBL15641252 | 0.79 | TSHR (0.36) | TSHRSMN1; SMN2KDM4EALDH1A1 | |
| SCHEMBL3016252 | 0.79 | KISS1R (0.37) | KDM4EKISS1RALDH1A1CARM1ALOX15 | |
| SCHEMBL2246543 | 0.79 | — | — | |
| SCHEMBL1290407 | 0.78 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100303734-A1 | CONTRAST AGENTS | GE HEALTHCARE AS (NO) | 2010-12-02 | — | — | US | disclosed |
| US-20100303734-A1 | CONTRAST AGENTS | GE HEALTHCARE AS (NO) | 2010-12-02 | — | — | US | disclosed |
| US-20100303734-A1 | CONTRAST AGENTS | GE HEALTHCARE AS (NO) | 2010-12-02 | — | — | US | disclosed |
| EP-2231200-A1 | CONTRAST AGENTS | GE Healthcare AS (NO) | 2010-09-29 | — | — | EP | disclosed |
| WO-2009071605-A1 | CONTRAST AGENTS | GE HEALTHCARE AS (NO) | 2009-06-11 | — | — | WO | disclosed |
| WO-2009071605-A1 | CONTRAST AGENTS | GE HEALTHCARE AS (NO) | 2009-06-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100303734-A1 | CONTRAST AGENTS | C1R, CNKSR1, C5 | TSHR 6/4885SMN1; SMN2 4013/4885KDM4E 4580/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.